POSSIBLE SIDE EFFECTS

Possible side effects of SARCLISA

Infusion reactions

Infusion icon

SARCLISA is given by a healthcare provider as an intravenous (IV) infusion into your vein. Medicines given by IV infusion can sometimes cause unwanted reactions.

Infusion reactions are common with SARCLISA and can sometimes be severe.

Infusion reactions are common with SARCLISA and can sometimes be severe.

Your healthcare provider will prescribe medicines before each infusion of SARCLISA to help decrease your risk for infusion reactions or to help make any infusion reaction less severe. You will be monitored for infusion reactions during each dose of SARCLISA.

Your healthcare provider may slow down or stop your infusion, or completely stop treatment with SARCLISA, if you have an infusion reaction.

Tell your healthcare provider right away if you develop any of the following symptoms of infusion reaction during or within 24 hours after an infusion of SARCLISA:

  • feeling short of breath
  • cough
  • chills
  • nausea

In the SARCLISA study, all infusion reactions started during the first infusion, typically within 24 hours. These infusion reactions resolved in the same day in most people.*

Decreased white blood cell counts

Drop icon

Decreased white blood cell counts are common with SARCLISA and certain white blood cells can be severely decreased. You may have an increased risk of getting certain infections, such as upper and lower respiratory infections.

Your healthcare provider will check your blood cell counts during treatment with SARCLISA. Your healthcare provider may prescribe an antibiotic or antiviral medicine to help prevent infection, or a medicine to help increase your white blood cell counts during treatment with SARCLISA.

Tell your healthcare provider right away if you develop any fever or symptoms of infection during treatment with SARCLISA.

Risk of new cancers

New cancers have happened in people during treatment with SARCLISA. In the SARCLISA study, 6 of the 154 people treated with SARCLISA developed new cancers. Five of these people continued treatment with SARCLISA and 1 stopped treatment. Your healthcare provider will monitor you for new cancers during treatment with SARCLISA.

Change in blood tests

SARCLISA can affect the results of blood tests to match your blood type. Your healthcare provider will do blood tests to match your blood type before you start treatment with SARCLISA. Tell all of your healthcare providers that you are being treated with SARCLISA before receiving blood transfusions.

Common side effects that may occur with SARCLISA

  • lung infection (pneumonia)
  • decreased red blood cell counts (anemia)
  • upper respiratory tract infection
  • decreased platelet counts (thrombocytopenia)
  • diarrhea
Cross icon

These are not all the possible side effects of SARCLISA. For more information, ask your healthcare provider or pharmacist.

SARCLISA is not chemotherapy. SARCLISA is a targeted immunotherapy that works with your immune system to fight Multiple Myeloma.

*In the study, 3 people also had infusion reactions at their second infusion and 2 people had infusion reactions at their fourth infusion.

Discussion icon

Use the SARCLISA Conversation Starter to help you have an informed discussion with your doctor at your next appointment.

Download

Sign-up icon

Stay up to date with the latest
information about SARCLISA.

Sign Up